SAGE 250117 7.50C (SAGE250117C7500) Stock Options, News & Quotes

US OptionsDetailed Quotes

SAGE250117C7500

Watchlist

0.05
0.000.00%

15min DelayClose Jan 17 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

TD Cowen Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Moomoo NewsJan 21 10:31 ET · Ratings
Piper Sandler Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Maintains Target Price $9
Moomoo NewsJan 21 07:31 ET · Ratings
Scotiabank Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Maintains Target Price $14
Moomoo NewsJan 21 07:31 ET · Ratings
Scotiabank Remains a Buy on SAGE Therapeutics (SAGE)
TipRanksJan 21 07:25 ET · Ratings
Piper Sandler Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)
TipRanksJan 21 06:49 ET · Ratings
Trending Stocks as Wall Street Bounces Back With Strong Week
Seeking AlphaJan 18 11:31 ET

Comments

Stock_Drift

Jan 12 17:27

$Sage Therapeutics (SAGE.US)$

Jaguar8

Jan 12 16:02

🟢 Watchlist JANUARY 13, 2025, Monday. NFA. Those with 🟢 are my top picks

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...

Jaguar8

Jan 10 17:49

ADDED NEWS

$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
Friday, 10th January at 6:49 pm
No Shareholder Action Required at This Time
Sage Therapeutics, Inc. (NASDAQ: SAGE) ("The Company"), today confirmed that Biogen Inc. (NASDAQ: BIIB) ("Biogen") has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share...

Jaguar8

Jan 10 16:43

NEWS

$Sage Therapeutics (SAGE.US)$
Biogen Inc - Submits Non-Binding Proposal to Buy All Outstanding Shares of Sage Therapeutics' Common Stock Not Owned by Biogen for $7.22/Share in Cash